Please ensure Javascript is enabled for purposes of website accessibility

China Approves a Treatment for COVID-19 Complications

By Cory Renauer - Mar 4, 2020 at 1:57PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drug, usually used to treat rheumatoid arthritis, could help prevent catastrophic organ failure in coronavirus patients.

China's National Health Commission published treatment guidelines Wednesday that could make a decade-old rheumatoid arthritis drug a treatment option for patients with severe SARS-CoV-2 infections.

Actemra from Roche (RHHBY) is used to dial down out-of-control immune system responses. It's been approved in the U.S. to treat patients with severe rheumatoid arthritis -- an autoimmune disease -- since 2010. It's also been approved to treat life-threatening bouts of cytokine release syndrome (CRS) brought on by super-potent new cancer therapies.

Paging Dr. Thumbs-up

Image source: Getty Images.

While the latest weapon in the battle against the novel coronavirus won't help with containing the epidemic, it could save the lives of patients fighting off infections. That's because when the immune system overreacts to an infection, the resulting cytokine release syndrome can lead to organ failure.

Don't try this at home

Usually, dialing back the immune system by any means would be the wrong move when fighting an infection. In fact, Actemra has a black box warning on its label because it makes it easier for infections to become life-threatening. The drug is likely to do far more harm than good to anybody who isn't already experiencing a severe immune system flare-up.

In the weeks ahead, ongoing studies in the U.S. and abroad should shed some light on the value of a number of potential treatments for COVID-19 that could be used more broadly. For example, Remdesivir is an experimental antiviral from Gilead Sciences (GILD), and there is some evidence that it's effective against other coronaviruses.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.